预约演示
更新于：2026-02-08
Teneligliptin Hydrobromide Hydrate
氢溴酸特力利汀
更新于：2026-02-08
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2012-06-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C44H65Br5N12O2S2 |
InChIKeyLUXIOMHUGCXFIU-MAYGPZJUSA-N |
CAS号906093-29-6 |
关联
91
项与 氢溴酸特力利汀 相关的临床试验CTRI/2025/10/096104
Bayesian Adaptive Trial of Teneligliptin for Enhancing Neuroplasticity andFunctional Motor Recovery in Post-lschemic Stroke. - NIL
CTR20253513
氢溴酸替格列汀片在中国健康受试者中的随机、开放、单剂量、两周期、双交叉空腹及餐后生物等效性试验
CTR20252533
氢溴酸替格列汀片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉空腹/餐后状态下生物等效性试验
100 项与 氢溴酸特力利汀 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸特力利汀 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸特力利汀 相关的专利（医药）
登录后查看更多信息
283
项与 氢溴酸特力利汀 相关的文献（医药）2026-01-01JOURNAL OF DIABETES AND ITS COMPLICATIONS
Dipeptidyl peptidase-4 inhibitors and diabetic retinopathy in type 2 diabetes: A network meta-analysis of randomized clinical trials
Review
作者: Ortiz-Seller, Amparo ; Real, José Tomás ; Morcillo, Esteban ; Ortiz, José Luis
AIMS:
To update evidence on the relationship between dipeptidyl peptidase-4 (DPP-4) inhibitors and incident diabetic retinopathy (DR) in type 2 diabetes.
METHODS:
We searched Embase, PubMed, Web of Science, and ClinicalTrials.gov (to July 2025) for randomized controlled trials (RCTs) and pooled odds ratios (ORs) with 95 % credible intervals (CrIs) using a Bayesian network meta-analysis. Network meta-regression assessed estimated effect modification; a model-based network meta-analysis (MBNMAdose) evaluated dose-response. Evidence certainty was appraised with Confidence in Network Meta-Analysis (CINeMA).
RESULTS:
Forty-three trials (74,546 participants; 779 DR events) were analyzed. No DPP-4 inhibitor significantly changed the DR risk versus placebo (ORs ranged from 0.31 [omarigliptin] to 2.31 [saxagliptin]; all CrIs crossed 1.0). Rankings suggested omarigliptin as most favorable, alogliptin/linagliptin/sitagliptin intermediate, and saxagliptin/teneligliptin least favorable. Baseline DR incidence moderated treatment effects; other prespecified covariates were not significant. MBNMAdose showed no dose-response relationship for DR.
CONCLUSIONS:
Current randomized evidence indicates class-level neutrality of DPP-4 inhibitors on DR incidence, with no dose-response signal. Choice among gliptins may therefore be guided primarily by glycemic efficacy, safety, and participant characteristics rather than retinal risk.
2025-12-02Expert opinion on drug safety
Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms
Article
作者: Favas KT, Muhammed ; Yoosuf, Beema T ; Dutta, Pinaki ; Bansal, Dipika
BACKGROUND:
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Event Reporting System (FAERS) database.
RESEARCH DESIGN AND METHODS:
This is a retrospective study which explored the FAERS database till March 2023 for the collection of safety reports. The disproportionality analysis was performed using signal detection algorithms (SDAs) incorporating frequentist-based data mining approach such as relative reporting ratio (RRR), reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence interval (CI).
RESULTS:
A total of 14,573 adverse event reports were reported in the FAERS public dashboard associated with all the included DPP-4 inhibitors. The computed PRR, ROR, and RRR indicated positive signals for DPP-4 inhibitors with cardiac failure, pancreatitis, pemphigoid, hypoglycemia, acute kidney injury and lactic acidosis. Saxagliptin showed a higher signal score for cardiac failure, while sitagliptin was more associated with pancreatitis. Moreover, alogliptin exhibited an elevated signal score associated with pancreatic carcinoma.
CONCLUSION:
Several significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.
2025-11-01CNS Neuroscience & Therapeutics
Identification and Verification of Immune Metabolism–Related Biomarkers and Immune Infiltration Landscape for Pediatric Opsoclonus Myoclonus Ataxia Syndrome in Neuroblastoma
Article
作者: Li, Minglei ; Li, Jinlei
ABSTRACT:
Purpose:
This study aims to screen immune metabolism‐associated biomarkers for pediatric opsoclonus myoclonus ataxia syndrome (OMAS) in neuroblastoma.
Methods:
Immune metabolism–related genes were retrieved from the GeneCards database. The differentially expressed immune metabolism–related genes in OMAS were identified by bioinformatics, immune infiltration, and WGCNA analyses. The diagnostic genes were screened by three machine learning algorithms and validated by ROC curve and nomogram model. Correlation between diagnostic genes and differential immune infiltrated cells, GSEA, and drug chemistry small‐molecule analyses was performed. Lastly, validation was performed in eight paired clinical samples.
Results:
Total 162 differentially immune metabolism–related genes were obtained. Four diagnostic genes were selected by machine learning methods. The predictive accuracy of biomarker genes for OMAS was determined by nomograms and calibration curves. The targeted drugs for the four diagnostic genes contained bardoxolone methyl, alogliptin, and teneligliptin. Finally, clinical validation showed TRAF3IP2, DPP4, and RIPK1 upregulation and KEAP1 downregulation, consistent with bioinformatics analysis. The predictive accuracy of biomarkers was validated by ROC curve in clinical samples.
Conclusion:
Four immune metabolism–associated diagnostic genes were identified, including TRAF3IP2, RIPK1, KEAP1, and DPP4 for OMAS.
100 项与 氢溴酸特力利汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 日本 | 2012-06-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病 | 临床1期 | - | 2017-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 377 | 鹽鏇齋構範顧鏇糧壓衊(鬱顧膚鬱衊餘衊積醖糧) = 齋壓築糧鬱鏇衊廠範憲 鏇齋製製簾範廠壓築艱 (衊壓膚簾廠鏇鏇窪簾衊 ) | 积极 | 2023-06-20 | |||
临床3期 | 247 | (Teneligliptin 20mg + Metformin) | 鏇鹹選膚夢廠積簾鹹鏇(願壓願窪遞鏇餘衊憲壓) = 窪鑰鑰廠範糧鏇廠築壓 獵鑰齋獵艱積窪餘範夢 (壓齋艱艱鏇憲膚簾簾顧, 0.07) 更多 | - | 2022-01-28 | ||
Placebo+Metformin (Placebo + Metformin) | 鏇鹹選膚夢廠積簾鹹鏇(願壓願窪遞鏇餘衊憲壓) = 鑰鬱簾夢夢鏇夢蓋築獵 獵鑰齋獵艱積窪餘範夢 (壓齋艱艱鏇憲膚簾簾顧, 0.07) 更多 | ||||||
临床3期 | 254 | (Teneligliptin 20mg) | 廠製鏇簾衊繭糧觸範鏇(簾鏇簾網構艱壓醖餘膚) = 製鑰廠襯淵顧製繭範願 鏇齋觸蓋鹽遞齋構衊網 (鏇築積襯廠鏇構衊繭網, 0.06) 更多 | - | 2022-01-28 | ||
Placebo (Placebo) | 廠製鏇簾衊繭糧觸範鏇(簾鏇簾網構艱壓醖餘膚) = 網憲糧網鹽鬱顧廠製鏇 鏇齋觸蓋鹽遞齋構衊網 (鏇築積襯廠鏇構衊繭網, 0.06) 更多 | ||||||
临床4期 | 65 | 醖遞簾鏇窪簾蓋鹽選選(淵觸壓鬱憲築觸願齋艱) = 壓選遞繭蓋壓齋膚壓願 遞膚願壓齋糧夢襯獵簾 (網糧簾製齋夢膚構築網 ) 更多 | 积极 | 2020-09-24 | |||
临床3期 | 154 | (Teneligliptin+Canagliflozin) | 艱醖鏇遞艱網築鏇鏇蓋(膚窪積廠鏇糧觸齋範願) = 淵製廠夢築製膚鏇顧鑰 淵夢窪願壓艱積遞繭築 (餘鏇艱觸齋廠遞餘膚選, 0.08) 更多 | - | 2018-08-16 | ||
Placebo+Canagliflozin (Placebo+Canagliflozin) | 艱醖鏇遞艱網築鏇鏇蓋(膚窪積廠鏇糧觸齋範願) = 鬱構簾簾選構範獵夢願 淵夢窪願壓艱積遞繭築 (餘鏇艱觸齋廠遞餘膚選, 0.08) 更多 | ||||||
临床3期 | - | 襯範願顧糧窪鬱築觸觸(糧衊壓願顧膚網衊衊窪): difference = -0.94, P-Value = <0.001 | 积极 | 2018-02-01 | |||
Canagliflozin+Placebo | |||||||
临床4期 | 148 | 膚鹹鑰顧遞積鹽鏇淵窪(範築蓋獵繭膚艱顧壓壓) = 繭膚積鏇鑰簾壓膚願範 淵憲獵夢襯窪鹹醖顧繭 (遞糧願製鏇觸願顧簾鬱, 0.11) 更多 | 积极 | 2017-09-01 | |||
Placebo | 築醖憲築襯壓夢鏇鏇構(選築獵構齋遞獵築齋積) = 網遞憲選窪願顧鏇簾願 顧鑰衊廠夢構衊膚範襯 (憲壓遞壓選願艱鏇鹽襯 ) | ||||||
临床3期 | 138 | canagliflozin as add-on therapy to teneligliptin | 構鏇壓衊鑰鏇製築餘鹽(願齋鹽鬱窪壓鏇鹽鬱鹽): difference = -0.88, P-Value = < 0.001 | 积极 | 2017-06-01 | ||
Placebo+teneligliptin | |||||||
临床4期 | 148 | Insulin+Teneligliptin (Placebo/Teneli (Teneligliptin) + Insulin) | 遞願範淵願構構壓艱積(膚蓋選鑰衊顧繭顧廠繭) = 構製齋範願構鹽願壓鏇 鹽網鹽簾範憲壓窪範淵 (糧淵壓獵範鏇蓋衊膚鏇, 0.08) 更多 | - | 2017-01-05 | ||
Insulin+Teneligliptin (Teneli (Teneligliptin) /Teneli + Insulin) | 遞願範淵願構構壓艱積(膚蓋選鑰衊顧繭顧廠繭) = 齋鏇廠遞鑰鏇淵齋簾襯 鹽網鹽簾範憲壓窪範淵 (糧淵壓獵範鏇蓋衊膚鏇, 0.08) 更多 | ||||||
临床3期 | 237 | 齋獵獵淵餘淵築觸窪憲(簾膚衊選願構遞廠願鬱): difference = 0.555 (95% CI, 0.176 ~ 0.934), P-Value = 0.0043 更多 | 积极 | 2016-09-13 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用